Get the app
USHealthcare

Achieve Life Sciences Inc (ACHV)

US · Healthcare · Biotechnology

$7.91+6.60%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-74.8M
EPS
$-0.28
EPS estimate
$-0.18

EPS came in at -0.28 against a street estimate of -0.18 — a miss of 55.6%.

Key statistics

Market cap
$753.2M
Forward P/E
35.3
P/B
64.03
Book value
$-0.14
EPS (TTM)
$-1.66
52-week high
$8.64
52-week low
$2.62
50-day MA
$7.05
200-day MA
$5.24
Beta
2.25

Analyst view

Analysts rate Achieve Life Sciences Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $13.83.

Shareholding

Insiders
0.91%
Institutions
81.95%

Largest institutional holders

FundStake
venBio Partners LLC5.75%
Logos Global Management LP5.27%
Paradigm Biocapital Advisors LP4.81%
Franklin Templeton Inc4.25%
Propel Bio Management LLC3.92%
Vivo Capital, LLC2.67%
Eventide Asset Management, LLC2.16%
Vanguard Capital Management, LLC2.14%

Recent filings & reports

DocumentDate
Company announcement · Q3 2026
ACHIEVE LIFE SCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company established an At-The-Market (ATM) offering program on August 14, 2026 • Maximu
2026-08-14
Quarterly report · Q2 2026
ACHIEVE LIFE SCIENCES, INC. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $47.96 million in cash + $139.35 million in marketable securi
2026-08-11
Results announced · Q3 2026
ACHIEVE LIFE SCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $187.3 million (June 3
2026-08-11
Charter / bylaws change · Q3 2026
ACHIEVE LIFE SCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held July 2, 2026 • Nine board directors elected with st
2026-07-06
Proxy statement · Q2 2026
PROXY STATEMENT SUMMARY FOR ACHIEVE LIFE SCIENCES, INC. WHAT SHAREHOLDERS ARE VOTING ON • Proposal One: Elect nine directors to serve until next ann
2026-06-08
Board / officer change · Q2 2026
ACHIEVE LIFE SCIENCES, INC. – 8-K SUMMARY HEADLINE NUMBERS • Two new board directors appointed effective May 29, 2026: Jeff Farrow and Reid Waldman,
2026-06-02
Quarterly report · Q1 2026
ACHIEVE LIFE SCIENCES, INC. — FORM 10-Q SUMMARY (Q1 2026) --- HEADLINE NUMBERS • Cash Position: $28.1 million in cash and cash equivalents as of Ma
2026-05-12
Annual report FY2025
ACHIEVE LIFE SCIENCES, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-s
2026-03-24

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Achieve Life Sciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.